As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than with mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies.

由于 COVID-19 对癌症患者产生不利影响，因此迫切需要采取预防策略。通过针对 SARS-CoV-2 刺突蛋白的经过验证的抗体测定，我们确定了纽约市 200 名癌症患者的高血清转化率 (94%)，这些患者接受了 FDA 批准的一种 COVID-19 疫苗的全额剂量。与实体瘤 (98%) 相比，血液系统恶性肿瘤患者 (85%) 的血清转化率显着较低，尤其是接受高度免疫抑制治疗的患者，例如抗 CD20 疗法 (70%) 和干细胞移植 (73 %）。接受免疫检查点抑制剂治疗（97%）或激素治疗（100%）的患者在疫苗接种后表现出高血清转化。既往感染过 COVID-19 的患者在接种疫苗后表现出较高的抗尖峰 IgG 滴度。与基于 mRNA 的疫苗相比，腺病毒疫苗接种后观察到的 IgG 滴度相对较低。这些数据表明，肿瘤患者中 COVID-19 疫苗接种通常具有较高的免疫原性，并确定了需要新型疫苗接种或被动免疫策略的免疫抑制群体。